Key Details
Price
$10.80Annual ROE
-40.80%Beta
1.41Events Calendar
Next earnings date:
Feb 25, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.
DUBAI, UAE, Jan. 26, 2025 /PRNewswire/ -- On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai , and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration. Speaking at the Yuwell Medical 2025 Global Core Partner Conference, Alex WU, Chairman of Yuwell Medical, stated that as a leading enterprise in China's home medical device industry, Yuwell will rely on internal growth and external mergers and acquisitions to promote internationalisation.
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
Call Start: 17:00 January 1, 0000 5:26 PM ET Inogen, Inc. (NASDAQ:INGN ) Q3 2024 Earnings Conference Call November 7, 2024, 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Mike Matson - Needham Operator Welcome to Inogen's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
FAQ
- What is the ticker symbol for Inogen?
- Does Inogen pay dividends?
- What sector is Inogen in?
- What industry is Inogen in?
- What country is Inogen based in?
- When did Inogen go public?
- Is Inogen in the S&P 500?
- Is Inogen in the NASDAQ 100?
- Is Inogen in the Dow Jones?
- When was Inogen's last earnings report?
- When does Inogen report earnings?
- Should I buy Inogen stock now?